Better business coming in than going out: management describes the quality of new intake visibly exceeding what it is re
The model's full reasoning — Q1 2022 call → NOWe need to determine if management conveys that the incoming business is of higher quality than the outgoing business, with a real turnover happening now, and that results will improve as the mix turns over. Let's examine the transcript. The call discusses OPKO's Q1 2022 results, the ModeX acquisition, BioReference Labs, etc. Key points: The company acquired ModeX, a biotech with innovative multi-specific immunotherapies. They also divested GeneDx to Sema4. They have a partnership with Pfizer for Somatrogon (long-acting growth hormone) which launched in Japan and Germany, triggering milestones. The question is about the business "taking in right now" vs "finishing, replacing, or letting run off". This could refer to the diagnostics segment (COVID testing declining) and the core business growing. Or the ModeX acquisition as new business vs old? Or the Somatrogon launches? Let's read carefully. Management discusses BioReference: "As COVID testing has waned, BioReference continues to focus on its strategy to grow our core diagnostic business, grow our specialty testing segments..." They mention volume in clinical base business increased 4% vs Q4, driven by preferred status with UnitedHealthcare and Aetna. Women's health, NIPT grew 219% year-over-year. Oncology up 5% over prior year. So they are growing core business while COVID declines. But is there a contrast in quality? They don't explicitly say the new business is higher margin or better priced. They talk about growth in volumes, but not necessarily better economics. They mention "Reach initiative" to take out costs. They also mention that COVID testing had higher cost to serve, and margins were impacted by labor costs. But they don't explicitly say that the incoming core business is higher quality than the outgoing COVID business. They might imply it, but they don't state it directly. The ModeX acquisition: They are bringing in a new business. But is that "taking in" business? It's an acquisition, not necessarily a contrast with outgoing business. They talk about the potential of ModeX, but not about it being better than existing business in terms of economics. The Somatrogon launches: Pfizer launched in Japan and Germany, triggering milestones. That's a product launch, but not necessarily a contrast between incoming and outgoing business.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| BBD | Banco Bradesco S.A. | Q3 2022 | 2022-11-09 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
HSTM · Q3 2017 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting incoming business against outgoing: - Patient Experience: "Existing clients also continue to convert from a phone modality to email and SMS text surveying modality... This conversion trend to continue... expected to have a positive impact... on patient experience margins." (lower price, higher margin shift already happening) - Provider Solutions: "the move from installed software sales to software as service sales... challenge revenue growth... but not profitability growth" and "backlog of unimplemented customers... significantly reduced" - Laerdal/HeartCode: "the new product we believe is right now based on contracts.
GFS · Q3 2021 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting the incoming business with the outgoing: compute revenue is declining "as expected" due to customers shifting to smaller nodes, while "newer high-margin customer designs" are ramping in 2H 2022 to offset it. They tie this directly to mix improvement from "d differentiated solutions become a larger portion" and "feature-rich" platforms (FDX, RF SOI, silicon photonics) growing while feature-rich CMOS is flat or down. LTAs signed now carry "pricing improvements" baked in for 2022+, with new agreements committing future capacity at those better terms.
CYBR · Q3 2021 → YESThe question is about whether management conveys that the new business they're taking in is of higher quality than the old business they're replacing, and that as the old rolls off, results will impro...YES Management explicitly contrasts the incoming subscription business (new logos, SaaS bookings, Privileged Cloud, EPM) as higher-quality than the outgoing perpetual license business it is replacing. They describe it as delivering “faster type of value,” “higher lifetime value over time,” and “more users and more products faster ,” while noting that the current revenue and profitability headwind from the mix shift is “obscuring the P&L” and that results will improve once the transition completes.